The price touched fair value on 10/7/2026: +12.37% from the DD reference price of $2.91. DD not tracked on social: the outcome is measured from the report reference price, not from a publication date. Thesis played out — this report is a historical document, no longer maintained.
Stock has round-tripped from $8+ to the 52-week low $2.85 (US$2.91) on dilution digestion (March 2026 $396.7M equity raise) and Katfish-contract timing anxiety. Backlog visibility is strong (C$355M+ 2026 product orders, Covelya closed July 2) and FY26 guidance C$290–320M revenue / C$65–75M EBITDA stands. The entire thesis now rests on a single procurement event — the pending Katfish SAS award — and successful Covelya integration (C$615M purchase price). Base case +12% upside, bull +60%, bear −40%. Asymmetry exists but is bimodal.
Primary = Sum-of-parts EV/EBITDA FY27E (Legacy Kraken 15x + Covelya 14x) + net cash − execution haircuts. Implied EV/Sales FY27E = 3.5x (within peer range). Scenario-weighted FV = 0.30×$4.80 + 0.45×$3.35 + 0.25×$1.95 = US$3.44 . Base case US$3.27 (consensus-triangulated) sits ~5% below scenario-weighted FV — appropriate conservatism given binary catalyst. Multiple sensitivity: ±2x EV/EBITDA on Covelya alone moves FV by ±C$0.30 (±US$0.22). ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Legacy Kraken EBITDA 2027E | Standalone C$70M revenue (products) × 25% EBITDA mg → C$17.5M × 15x = C$263M EV / 340M sh | +0.77 |
| Covelya EBITDA 2027E | C$220M revenue (services + ODOBN launch) × 24% EBITDA mg → C$53M × 14x = C$742M EV / 340M sh | +2.18 |
| UUV battery OEM option | 10 new OEM customers 12-20 months → prob 60% × C$80M NPV / 340M sh | +0.14 |
| Net cash | C$91M cash − C$40M LTD = C$51M net / 340M sh | +0.15 |
| Katfish execution haircut | Prob 25% of guidance miss × C$150M EV reduction / 340M sh | −0.11 |
| Further dilution reserve | Potential 2027 financing or earn-out at prob 20% × 5% dilution | −0.10 |
| FV base case (C$) | Sum: +0.77 +2.18 +0.14 +0.15 −0.11 −0.10 = C$3.03/sh | ≈ C$3.03 |
Short interest is low — this is NOT a crowded-short situation. The drawdown is driven by shareholder exits (post-raise rotation), not aggressive shorting. Translation: no short squeeze catalyst; the recovery has to come from fundamentals (Katfish, earnings), not positioning unwind.
| Item (C$M) | FY2024 | FY2025 | FY2026E | FY2027E | FY2028E |
|---|---|---|---|---|---|
| Revenue | 91.3 | 102.2 | 305 (mid) | 390 | 470 |
| Products | 55 | 65 | 230 | 290 | 345 |
| Services (incl. Covelya) | 36 | 37 | 75 | 100 | 125 |
| Gross margin (%) | 52 | 55 | 56 | 58 | 58 |
| Adj EBITDA | 20 | 22 | 70 | 105 | 135 |
| Adj EBITDA margin (%) | 21.9 | 21.5 | 23.0 | 26.9 | 28.7 |
| Net income (GAAP) | 5 | 3 | −5 | 30 | 55 |
| FCF | 8 | −20 | −10 | 30 | 70 |
| Shares outstanding (M) | 215 | 232 | 340 | 345 | 347 |
FY26E assumes full-year Kraken + half-year Covelya (6 months July–December). FY27E is first clean year of combined entity. FCF turns positive 2027 as capex normalizes (C$27–33M in 2026 is elevated for capacity build; 2027 should drop to C$20–25M). Growth decelerates to +25% FY27 and +20% FY28 as backlog converts; longer-term, defense procurement cycles (Royal Navy, NATO, US Navy) and ODOBN commercial launch extend the ramp into 2028.
Quarterly trend
| Period | Revenue (C$M) | Products | Services | Gross mg | Adj EBITDA | Cash (C$M) |
|---|---|---|---|---|---|---|
| Q2 2025 | 26.4 | 16.0 | 10.4 | 56% | 4.7 | 32.9 |
| Q3 2025 | 28.5 | 17.5 | 11.0 | 55% | 5.9 | 45.0 |
| Q4 2025 | 28.0 | 17.5 | 10.5 | 54% | 6.0 | 38.0 |
| Q1 2026 | 22.5 | 14.0 | 8.5 | 52% | 3.5 | 425.0* |
| Q2 2026 | 27.3 | 17.0 | 10.3 | 59% | 5.0 | 91.3* |
* Q1 2026 cash reflects the C$396.7M equity raise held in escrow; Q2 2026 reflects deployment into Covelya closing (Covelya closed July 2 so cash exit is actually post-period). Q1 2026 revenue dip was pre-planned seasonality; Q2 recovered with product orders accelerating. The real story is on the ORDERS line: C$355M of 2026 product orders secured by August is 3.5x FY25 revenue — this is a Q4-weighted conversion story.
Business units & competitive position
Subsea Batteries (SeaPower) ~C$90–110M FY26E (30% rev) 🟢 RAMP Pressure-tolerant Li-ion for UUV/AUV. ~10 new OEM customers in 18 months — embedded across 30+ platforms. 55–60% gross margin. Highest IP moat. Synthetic Aperture Sonar (SAS) ~C$80–100M FY26E (28% rev) 🟢 RAMP AquaPix & Katfish towed systems. NATO navies, Royal Navy £12.3M USV contract (Mar 2026), US Navy evaluations. Katfish 2026 award is the single biggest catalyst. Covelya — Services & Software ~C$75M FY26E (25% rev, half-year) 🟢 INTEGRATION Acquired July 2 for C$615M. Mission-critical subsea intelligence, contract services for defense & energy. Adds 750 employees, UK/EU exposure. Risk = execution. Navigation Systems ~C$30–40M FY26E (12% rev) 🟡 TRANSITION INS/DVL for underwater positioning. Steady defense book. Lower margin (40%) but sticky — once specified into UUV, locked for life of platform. ODOBN (Seismic Nodes) ~C$0 FY26 / C$30M FY27E (option) 🟡 PRE-COMMERCIAL Covelya-acquired on-demand ocean bottom nodes — offshore oil & gas seismic. Commercial launch planned 2027. Could add C$30–60M revenue 2027–2028 if traction. Ocean Science / Other ~C$15M FY26E (5% rev) 🟡 MIXED Research vessels, carbon capture monitoring, harbour security sonar. Niche but growing — carbon capture is a 2028+ tailwind if CCS projects scale.
Competitive moat: HIGH on batteries (10 OEM lock-ins, 2–3 year design-in cycle), MEDIUM on SAS (TKMS, Thales, HII compete but Kraken wins on cost/performance in mid-market), LOWER on services (Covelya competes with ECA Group, Fugro, Oceaneering in a fragmented market). Overall moat improving with scale from Covelya but not best-in-class. The Covelya acquisition is strategically correct (vertical integration into services) but doubles execution risk during a down-market.
Risk grid
SWOT
- +C$355M+ 2026 product orders — 3.5x FY25 revenue backlog
- +59% Q2 gross margin — best among subsea tech peers
- +10 UUV battery OEM wins in 18 months — platform lock-in
- +C$91M cash + C$152M working capital = funded through 2027
- +RBC Capital Outperform C$6 target (+105% vs spot)
- −OTCQB listing — thin liquidity, no index inclusion, limited institutional
- −Revenue heavily Q4-weighted — low Q3 visibility
- −60% share dilution 2024→2026 — per-share compounding dampened
- −Negative FCF through 2026 — capex-heavy expansion phase
- −Single-point Katfish dependency for FY26 EBITDA guidance
- →Katfish SAS award Q4 2026 / Q1 2027 — multiple expansion trigger
- →ODOBN commercial launch 2027 — new offshore energy vertical
- →Mine countermeasure cycle 2026–2030 = 3x prior-period activity
- →Covelya cross-sell — subsea batteries into existing services base
- →Carbon capture monitoring — adjacent growth 2028+
- !Katfish lost to competitor (HII, Thales) — bear case trigger
- !Covelya integration failures — goodwill writedown risk
- !Defense budget shocks (US shutdown, NATO cuts, UK austerity)
- !CAD/USD volatility — margin compression above 0.78
- !Second equity raise 2027 if growth accelerates beyond cash
Investor profile summary
- Small-cap defense/robotics specialists sized ≤2% position
- Investors with 12–24 month horizon (post-Katfish decision)
- Thematic plays on NATO/AUKUS undersea sovereignty
- Patient capital tolerant of OTC liquidity + CAD exposure
- Katfish contract award (binary) — Q4 2026 / Q1 2027
- Q3 2026 earnings (late Nov) — Covelya first-quarter contribution
- Backlog burn — FY26 revenue conversion from C$355M book
- UUV battery OEM count — currently 10, target 15 by YE 2027
- Yield investors — no dividend, won't initiate near-term
- Momentum traders — stock in protracted downtrend
- Large-cap-only funds — illiquid OTC, insufficient scale
- Investors needing GAAP profitability — net loss through 2026
Report metadata. Market data — last verified close 2026-10-02 (T-1 trading days vs 2026-10-05 report date). Price US$2.91 confirmed by Fool.com, Stocktwits (both as "today, −3.30%" when read on 2026-10-05), consistent with StockAnalysis.com Oct 1 close ($3.009) → Oct 2 close ~$2.91. CAD/USD 0.735 used for conversions. Fundamentals from Kraken Robotics Q2 2026 earnings release (2026-08-27), earnings call (BigGo Finance, Fool.com transcripts), investor presentations, Marketbeat short interest (2026-09-15), insider transaction filings. All forward estimates are the author's modeling except where identified as official guidance (FY26 C$290–320M revenue, C$65–75M EBITDA). Peer multiples sourced from Oct 2026 consensus data. Not investment advice. For analytical use only. ⚠️ Not investment advice.